<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563472</url>
  </required_header>
  <id_info>
    <org_study_id>PR3081</org_study_id>
    <nct_id>NCT00563472</nct_id>
  </id_info>
  <brief_title>Feasibility Study Into the Contraceptive Effect of Estetrol</brief_title>
  <official_title>A Feasibility Study Into the Contraceptive Effect of Estetrol Alone or Combined With Either Progesterone or Desogestrel by Daily Oral Administration to Healthy Female Volunteers for 28 Days.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pantarhei Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pantarhei Bioscience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open study in 50 young, healthy, female volunteers. Women who want to participate&#xD;
      and who are using hormonal contraception stop using their hormonal contraceptive and wait for&#xD;
      their first spontaneous menstruation (i.e. after a wash-out cycle). Women who do not use&#xD;
      hormonal contraception wait for their next menstruation. From the 9th day after start of the&#xD;
      menstruation onwards follicle growth will be monitored by ultrasonography until ovulation&#xD;
      occurs or until day 24 after start of their menses. Women who ovulate within 24 days after&#xD;
      start of their menses will be eligible to participate and will be stratified in one of 4&#xD;
      groups: 10 mg estetrol (E4) alone, 20 mg E4 alone, 20 mg E4 combined with 150 mcg desogestrel&#xD;
      and 20 mg E4 combined with 200 mg progesterone. The subjects will be treated for 28 days.&#xD;
      Treatment will start on the first day of their menses after the pre-treatment cycle.&#xD;
&#xD;
      During the study period (28 days) the activity of the hypothalamic-pituitary-ovarian (HPO)&#xD;
      axis will be investigated by measuring follicular development using ultrasonography and by&#xD;
      determining serum concentrations of Follicle Stimulating Hormone (FSH), Luteinising Hormone&#xD;
      (LH), estradiol (E2) and Progesterone (P).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ovulation inhibition</measure>
    <time_frame>during treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>endocrine parameters</measure>
    <time_frame>during treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg estetrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg estetrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg estetrol and 150 microg desogestrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg E4 and 200 mg progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol</intervention_name>
    <description>10 mg orally per day for 28 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol</intervention_name>
    <description>20 mg orally per day for 28 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol and desogestrel</intervention_name>
    <description>20 mg estetrol and 150 microg desogestrel orally per day for 28 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estetrol and progesterone</intervention_name>
    <description>20 mg estetrol and 200 mg progesterone orally per day for 28 days</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years and not older than 40 years of age&#xD;
&#xD;
          -  Willing to use a barrier method of contraception during the wash-out cycle, the&#xD;
             pre-treatment cycle, the period of study drug administration, the period of&#xD;
             lynestrenol intake (if applicable), and 14 days thereafter or until the follow-up&#xD;
             visit if this 14-days period ends before the follow-up visit.&#xD;
&#xD;
          -  Women who ovulate in the pre-treatment cycle before or on day 24 (Â±1) after start of&#xD;
             their menses, who have a subsequent P concentration of &gt; 16 nmol/l and whose next&#xD;
             menstruation does not start within 6 days after ovulation&#xD;
&#xD;
          -  Body Mass Index &gt; 18 and &lt;30 kg/m2&#xD;
&#xD;
          -  Good physical and mental health&#xD;
&#xD;
          -  Both ovaries visible upon ultrasonography&#xD;
&#xD;
          -  Willing to give informed consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormal results of routine hematology, serum biochemistry,&#xD;
             urinanalysis, and/or ECG in the opinion of the Investigator at screening.&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Pregnancy during accurate hormonal contraceptive use&#xD;
&#xD;
          -  Known or suspected breast cancer or a history of breast cancer&#xD;
&#xD;
          -  Clinically significant abnormalities of the uterus and/or ovaries detected by&#xD;
             examination and/or ultrasound (non-physiological ovarian mass or significant uterine&#xD;
             pathology).&#xD;
&#xD;
          -  A cervical smear with clinically relevant abnormal cytology within one year before&#xD;
             study start.&#xD;
&#xD;
          -  Previous use of depot progestogen preparations in the last 6 months.&#xD;
&#xD;
          -  Contraindications for contraceptive steroids:&#xD;
&#xD;
               -  a history of, or existing thromboembolic, cardiovascular or cerebrovascular&#xD;
                  disorder&#xD;
&#xD;
               -  a history of, or existing conditions predisposing to, or being prodromi of, a&#xD;
                  thrombosis&#xD;
&#xD;
               -  a known defect in the blood coagulation system (e.g. deficiencies in AT-III,&#xD;
                  protein C, S, and APC resistance)&#xD;
&#xD;
               -  heterozygous for a mutation in coagulation factor II and/or positive for factor V&#xD;
                  Leiden&#xD;
&#xD;
               -  the presence of a severe or more than one risk factor for vascular disease (e.g.&#xD;
                  dyslipoproteinaemia; diabetes mellitus; hyperhomocysteinaemia; systemic lupus&#xD;
                  erythematosus; chronic inflammatory bowel disease; antiphospholipid antibodies;&#xD;
                  smoking; venous thromboembolism in sibling or parent below the age of 50, or&#xD;
                  arterial disease in sibling or parent below the age of 35; within 2 weeks after&#xD;
                  full remobilisation following surgery)&#xD;
&#xD;
               -  hypertension, i.e. systolic blood pressure &gt;140 mmHg and/or diastolic blood&#xD;
                  pressure &gt;90 mmHg&#xD;
&#xD;
               -  disturbance of liver function: e.g. cholestatic jaundice, a history of jaundice&#xD;
                  of pregnancy or jaundice due to previous oestrogen use, Rotor syndrome and&#xD;
                  Dubin-Johnson syndrome&#xD;
&#xD;
               -  known or suspected hormone-dependent tumours or endometrial hyperplasia&#xD;
&#xD;
               -  undiagnosed vaginal bleeding&#xD;
&#xD;
               -  porphyria&#xD;
&#xD;
               -  a history during pregnancy or previous hormone-use of severe pruritus, herpes&#xD;
                  gestationis or deterioration of otosclerosis&#xD;
&#xD;
          -  Use of one or more of the following medications:&#xD;
&#xD;
               -  sex steroids other than the medication of study&#xD;
&#xD;
               -  use at present or within 2 months before start study medication:&#xD;
&#xD;
               -  hydantoins, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate,&#xD;
                  troglitazone, felbamate, rifampicin, rifabutin, griseofulvin and St. John's wort&#xD;
                  (Hypericum perforatum)&#xD;
&#xD;
          -  Status post-partum or post-abortion within a period of 2 months before study start&#xD;
&#xD;
          -  Administration of investigational drugs within 3 months before start study medication&#xD;
&#xD;
          -  A history of (within 12 months) alcohol or drug abuse&#xD;
&#xD;
          -  A known hypersensitivity for one of the components of the study medication (eg&#xD;
             arachisoil and lactosis)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Coelingh Bennink, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pantarhei Bioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dinox</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>November 22, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy female volunteers will participate in this study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

